RxDoctor Payments Data

Michelle Dallapiazza, MD

Infectious Disease · Chicago, ILNPI 1871656215

Payments from drug & device makers

$708in general payments, 2019–2025

Across 36 payments — averaging $19.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$424
  • Theratechnologies Inc.$91
  • Merck$68
  • Napo Pharmaceuticals Inc$33
  • Inspire Medical Systems, Inc.$25
  • Exact Sciences$24
  • plus $44 from 2 others

What the payments were for

  • Food & beverage$708100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$708 in reported general payments places this provider in the 65th percentile of 368 infectious disease providers in Illinois.

See all infectious disease providers in Illinois

Medicare billing

Part B allowed, 2024
$8,545
Medicare patients
32
Services billed
90

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala206$831,440
CabenuvaCabotegravir/Rilpivirine25$147,937
JulucaDolutegravir/Rilpivirine32$109,306
TivicayDolutegravir Sodium38$82,986
TriumeqAbacavir/Dolutegravir/Lamivudi17$61,040
DescovyEmtricitabine/Tenofov Alafenam28$60,004
PrezcobixDarunavir/Cobicistat23$56,196
PifeltroDoravirine17$28,590
Atovaquone31$12,983
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl25$7,705
JardianceEmpagliflozin12$7,271
AmbienZolpidem Tartrate11$7,082
SymbicortBudesonide/Formoterol Fumarate20$4,670
Naloxone Hcl40$3,112
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate15$2,990

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$22$891,444234 claims
Viiv Healthcare CompanyCabenuva, Juluca, Tivicay, Triumeq$424$401,269112 claims
MerckPifeltro$68$28,59017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 368 infectious disease providers in Illinois.

Other infectious disease in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →